Ablation von Lungentumoren mittels Radiofrequenz und Mikrowelle

Fazit

Die perkutane Thermoablation ist eine wesentliche Ergänzung bestehender Therapieverfahren pulmonaler Neoplasien. Die Technik ist jedoch in der Anwendbarkeit begrenzt. Die bisher vorliegenden Daten sind in Umfang und Qualität begrenzt, zeigen jedoch, dass in erfahrenen Händen mit etablierten Techniken vergleichbare Resultate erzielt werden können.

• Literatur

• 1 Gaber E. Sterblichkeit, Todesursachen und regionale Unterschiede. In: Gesundheitsberichterstattung des Bundes. Berlin: Robert-Koch-Institut; 2011
• 2 Farrell JT. Pulmonary metastasis: a pathologic, clinical, roentgenologic study based on 78 cases seen at necropsy. Radiology 1935; 24: 444-451
• 3 Zervas NT, Kuwayama A. Pathological characteristics of experimental thermal lesions. Comparison of induction heating and radiofrequency electrocoagulation. J Neurosurg 1972; 37: 418-422
• 4 Pennes HH. Analysis of tissue and arterial blood temperature in the resting human forearm. J Appl Physiol 1948; 1: 93-122
• 5 Bruners P, Hodenius M, Günther RW et al. Flüssigkeitsmodulierte RF-Ablation: In-vitro-Experimente. Röfo 2007; 179: 380-386
• 6 Pereira PL, Trübenbach J, Schmidt D. Radiofrequenzablation: Grundlagen, Techniken und Herausforderungen. Röfo 2003; 175: 20-27
• 7 D’Arsonval MA. Action physiologique des courants alternatifs. CR Sco Biol 1891; 43: 283-286
• 8 Dupuy DE, Zagoria RJ, Akerley W et al. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol 2000; 174: 57-59
• 9 Brace CL. Microwave ablation technology: What every user should know. Curr Probl Diagn Radiol 2009; 38: 61-67
• 10 Erinjeri JP, Clark TW. Cryoablation: mechanism of action and devices. J Vasc Interv Radiol 2010; 21 (08) 187-S191
• 11 Goeckenjan G, Sitter H, Thomas M et al. German Respiratory Society, German Cancer Society. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft – Kurzfassung. Pneumologie 2011; 65: e51-e75
• 12 Hasskarl J, Digel W, Waller CF. Lungenkarzinom. In: Berger D, Engelhardt R, Mertelsmann R, (Hrsg.) Das Rote Buch: Hämatologie und Internistische Onkologie. Landsberg: Ecomed; 2010
• 13 Stacul F, van der Molen AJ, Reimer P et al. Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Contrast induced Eur Radiol 2011; 21: 2527-2541
• 14 Wittekind J, Meyer HJ. TNM Klassifikation maligner Tumoren. Weinheim: Wiley-VCH; 2010
• 15 Skonieczki BD, Wells C, Wasser EJ et al. Radiofrequency and microwave tumor ablation in patients with implanted cardiac devices: Is it safe?. Eur J Radiol 2011; 79: 343-346
• 16 Yamamoto A, Nakamura K, Matsuoka T et al. Radiofrequency ablation in a porcine lung model: correlation between CT and histopathologic findings. AJR Am J Roentgenol 2005; 185: 1299-1306
• 17 Okuma T, Matsuoka T, Yamamoto A et al. Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study. Br J Radiol 2009; 82: 989-994
• 18 Akeboshi M, Yamakado K, Nakatsuka A et al. Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. J Vasc Interv Radiol 2004; 15: 463-470
• 19 Suzawa N, Yamakado K, Takao M et al. Detection of local tumor progression by (18)F-FDG PET/CT following lung radiofrequency ablation: PET versus CT. Clin Nucl Med 2013; 38: e166-e170
• 20 Higaki F, Okumura Y, Sato S et al. Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor. Ann Nucl Med 2008; 22: 157-163
• 21 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60
• 22 Herrera LJ, Fernando HC, Perry Y et al. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg 2003; 125: 929-937
• 23 Abtin FG, Eradat J, Gutierrez AJ et al. Radiofrequency ablation of lung tumors: imaging features of the postablation zone. Radiographics 2012; 32: 947-969
• 24 Goldberg SN, Gazelle GS, Compton CC et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. Acad Radiol 1995; 2: 776-784
• 25 Feng W, Liu W, Li C et al. Percutaneous microwave coagulation therapy for lung cancer. Zhonghua Zhong Liu Za Zhi 2002; 24: 388-390
• 26 Lencioni RR, Crocetti L, Cioni R et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-totreat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 2008; 9: 621-628
• 27 Fernando HC, De Hoyos A, Landreneau RJ et al. Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg 2005; 129: 639-644
• 28 Pennathur A, Luketich JD, Abbas G et al. Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg 2007; 134: 857-864
• 29 Hiraki T, Gobara H, Iishi T et al. Percutaneous radiofrequency ablation for clinical stage I non-small cell lung cancer: results in 20 nonsurgical candidates. J Thorac Cardiovasc Surg 2007; 134: 1306-1312
• 30 Beland MD, Wasser EJ, Mayo-Smith WW et al. Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology 2010; 254: 301-307
• 31 Hiraki T, Gobara H, Mimura H et al. Percutaneous radiofrequency ablation of clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2011; 142: 24-30
• 32 Ambrogi MC, Fanucchi O, Cioni R et al. Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study. J Thorac Oncol 2011; 6: 2044-2051
• 33 Lanuti M, Sharma A, Willers H et al. Radiofrequency ablation for stage I non-small cell lung cancer: management of locoregional recurrence. Ann Thorac Surg 2012; 93: 921-928
• 34 Kodama H, Yamakado K, Takaki H et al. Lung radiofrequency ablation for the treatment of unresectable recurrent non-small-cell lung cancer after surgical intervention. Cardiovasc Intervent Radiol 2012; 35: 563-569
• 35 Zemlyak A, Moore WH, Bilfinger TV. Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer. J Am Coll Surg 2010; 211: 68-72
• 36 Kim SR, Han HJ, Park SJ et al. Comparison between surgery and radiofrequency ablation for stage I non-small cell lung cancer. Eur J Radiol 2012; 81: 395-399
• 37 Lee H, Jin GY, Han YM et al. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. Cardiovasc Intervent Radiol 2012; 35: 343-350
• 38 Yan TD, King J, Sjarif A et al. Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival. Ann Surg Oncol 2006; 13: 1529-1537
• 39 Yan TD, King J, Ebrahimi A et al. Hepatectomy and lung radiofrequency ablation for hepatic and subsequent pulmonary metastases from colorectal carcinoma. J Surg Oncol 2007; 96: 367-373
• 40 Yamakado K, Hase S, Matsuoka T et al. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan. J Vasc Interv Radiol 2007; 18: 393-398
• 41 Chua TC, Thornbury K, Saxena A et al. Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Cancer 2010; 116: 2106-2114
• 42 Hamada A, Yamakado K, Nakatsuka A et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol 2012; 30: 567-574
• 43 Kim TS, Lim HK, Lee KS et al. Imaging-guided percutaneous radiofrequency ablation of pulmonary metastatic nodules caused by hepatocellular carcinoma: preliminary experience. AJR Am J Roentgenol 2003; 181: 491-494
• 44 Hiraki T, Yamakado K, Ikeda O et al. Percutaneous radiofrequency ablation for pulmonary metastases from hepatocellular carcinoma: results of a multicenter study in Japan. J Vasc Interv Radiol 2011; 22: 741-748
• 45 Shu YanHuo A, Lawson MD, King J et al. Use of percutaneous radiofrequency ablation in pulmonary metastases from renal cell carcinoma. Ann Surg Oncol 2009; 16: 3169-3175
• 46 Soga N, Yamakado K, Gohara H et al. Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma. BJU Int 2009; 104: 790-794
• 47 Ding JH, Chua TC, Glenn D et al. Feasibility of ablation as an alternative to surgical metastasectomy in patients with unresectable sarcoma pulmonary metastases. Interact Cardiovasc Thorac Surg 2009; 9: 1051-1053
• 48 Palussière J, Italiano A, Descat E et al. Sarcoma lung metastases treated with percutaneous radiofrequency ablation: results from 29 patients. Ann Surg Oncol 2011; 18: 3771-3777
• 49 Wolf FJ, Grand DJ, Machan JT et al. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology 2008; 247: 871-879
• 50 Lu Q, Cao W, Huang L et al. CT-guided percutaneous microwave ablation of pulmonary malignancies: results in 69 cases. World J Surg Oncol 2012; 10: 80
• 51 Vogl TJ, Naguib NN, Gruber-Rouh T et al. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. Radiology 2011; 261: 643-651
• 52 Liu H, Steinke K. High-powered percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: a preliminary study. J Med Imaging Radiat Oncol 2013; 57: 466-474
• 53 Brace CL, Hinshaw JL, Laeseke PF et al. Pulmonary thermal ablation: comparison of radiofrequency and microwave devices by using gross pathologic and CT findings in a swine model. Radiology 2009; 251: 705-711
• 54 Simon CJ, Dupuy DE, DiPetrillo TA et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 2007; 243: 268-275
• 55 Okuma T, Matsuoka T, Yamamoto A et al. Determinants of local progression after computed tomography-guided percutaneous radiofrequency ablation for unresectable lung tumors: 9-year experience in a single institution. Cardiovasc Intervent Radiol 2010; 33: 787-793
• 56 Vogl TJ, Worst TS, Naguib NN et al. Factors influencing local tumor control in patients with neoplastic pulmonary nodules treated with microwave ablation: a risk-factor analysis. AJR Am J Roentgenol 2013; 200: 665-672
• 57 Kashima M, Yamakado K, Takaki H et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center’s experiences. AJR Am J Roentgenol 2011; 197: W576-W580
• 58 Dupuy DE. Image-guided thermal ablation of lung malignancies. Radiology 2011; 260: 633-655
• 59 Nomura M, Yamakado K, Nomoto Y et al. Complications after lung radiofrequency ablation: risk factors for lung inflammation. Br J Radiol 2008; 81: 244-249
• 60 Renaud S, Falcoz PE, Olland A et al. Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery?. Interact Cardiovasc Thorac Surg 2013; 16: 68-73
• 61 von Meyenfeldt EM, Wouters MW, Fat NL et al. Local treatment of pulmonary metastases: from open resection to minimally invasive approach? Less morbidity, comparable local control.. Surg Endosc 2012; 26: 2312-2321
• 62 Fiorentino F, Treasure T. Pulmonary metastasectomy for colorectal cancer: Making the case for a randomized controlled trial in the zone of uncertainty. J Thorac Cardiovasc Surg 2013; 146: 748-752
• 63 Tampellini M, Ottone A, Bellini E et al. The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. Oncologist 2012; 17: 1430-1438
• 64 Schoellnast H, Deodhar A, Hsu M et al. Recurrent non-small cell lung cancer: evaluation of CT-guided radiofrequency ablation as salvage therapy. Acta Radiol 2012; 53: 893-899
• 65 Furukawa K, Miura T, Kato Y et al. Microwave coagulation therapy in canine peripheral lung tissue. J Surg Res 2005; 123: 245-250